Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller

Slides:

Advertisements

Similar presentations

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children Daihong.

Advertisements

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.

Impact of Donor Characteristics and HLA Matching on Survival of Chinese Patients with Hematologic Malignancies Undergoing Unrelated Hematopoietic Stem.

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,

Sabina Kersting, Leo F. Verdonck

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-

Biology of Blood and Marrow Transplantation

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Betty T. Tran, Abigail Halperin, Jason W. Chien

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe.

Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G

Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents.

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation Filippo Milano, Margaret A. Au,

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation Walter J.F.M.

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease Anna B. Pawlowska, Jerry C. Cheng,

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.

Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical.

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children Xiaojun.

Blood and Marrow Transplant Handbook

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Mammen Chandy Biology of Blood and Marrow Transplantation

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Optimal Donor Selection: Beyond HLA

Presentation transcript:

HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller Biology of Blood and Marrow Transplantation Volume 16, Issue 1, Pages S57-S63 (January 2010) DOI: 10.1016/j.bbmt.2009.10.032 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Treatment schema for nonmyeloablative conditioning and HLA-haploidentical bone marrow transplantation. From ref. 11. Biology of Blood and Marrow Transplantation 2010 16, S57-S63DOI: (10.1016/j.bbmt.2009.10.032) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Effect of HLA-DRB1 antigen mismatch (a,c) or HLA Class I allele mismatches (b,d) in the GVH direction on relapse, NRM (a,b), and EFS (c,d) after nonmyeloablative, HLA-haploidentical bone marrow transplantation with high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation 2010 16, S57-S63DOI: (10.1016/j.bbmt.2009.10.032) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 The myeloablative conditioning regimen for HLA-haploidentical HSCT at Peking University. Ara-C: cytosine arabinoside; Bu: busulfan; Cy: cyclophosphamide; MeCCNU: simustine; ATG: antithymocyte globulin. Biology of Blood and Marrow Transplantation 2010 16, S57-S63DOI: (10.1016/j.bbmt.2009.10.032) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions